Viatris Inc (VTRS) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
November 6, 2025 6:59 AM ESTDelivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch Acquires Aculys Pharma Including Rights to Pitolisant in Japan and Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region Returns More Than $920 Million of Capital to Shareholders Year-to-Date, Including $500 Million in Share Repurchases Raises and Narrows 2025 Financial Guidance Ranges for Total Revenues, Adjusted EBITDA and Adjusted EPS[1]
... More
